Research has demonstrated that, in comparative studies of anti-diabetic drugs, GLP-1RAs can significantly reduce the risk of liver decompensation and hepatocellular carcinoma in patients with type 2 diabetes [42]
In addition to meaningful weight loss, MariTide demonstrated a robust and sustained reduction in hemoglobin A1c (HbA1c) of up to 2.2% 1 in people living with obesity and T2D
The liver benefits require attention, particularly for patients with fatty liver disease
These medications help reduce appetite, improve satiety, and support sustainable weight loss when combined with healthy lifestyle habits
Types of GLP-1 travel cases compared Travel cases for injectable medications fall into four main categories
Cardiovascular safety In terms of cardiovascular safety, IDegLira contains liraglutide, the only Federal Drug Administration (FDA) approved GLP-1RA shown to reduce cardiovascular risk